Dados do Trabalho

Título

Safety and effectiveness of COVID19 vaccination in Multiple Sclerosis patients – interim analysis of a multi-center study

Resumo

INTRODUCTION
Multiple sclerosis (MS) is the most common immune-mediated demyelinating disease of the central nervous system. COVID-19 infected more than 535 million people worldwide. The most promising solution remains an effective vaccine. Given the autoimmune condition of MS, questions have arisen as to whether vaccination for COVID-19 confers effective immunity or whether it could represent a trigger for EM attacks.
OBJECTIVE
Report the clinical features and possible adverse effects of COVID-19 vaccination in patients with MS. Describe clinical events in patients diagnosed with MS that are subsequent to vaccination. Show possible changes in functional classification after vaccine exposure.
METHOD
Cross-sectional clinical study. Applied questionnaire directed to patients diagnosed with MS of patients followed up at the Hospital Universitario Walter Cantídio and Hospital Geral de Fortaleza. Data collected between January and February 2022 includes age,gender,vaccine used,side effects,number of MS attacks,clinical form of MS,EDSS,COVID infection. Statistical analysis was descriptive. Continuous variables were described by their means and standard deviations (SD).
RESULTS
Total of 13 participants,10 female and 3 male. Mean age of 43.7 years,SD of 16.9.Predominance of complete higher education (5 participants) and born in Fortaleza (6 participants).Only 1 patient had not been vaccinated with any dose and,of the 12 vaccinated,only 1 had not taken the booster dose. Vaccines applied in immunization:BNT162b1,ChAdOx1 and COVID-19 Adsorbed Vaccine (inactivated).4 patients reported mild side-effects, all after ChAdOx1 vaccine.2 vaccinated patients had COVID-19 after vaccination. No MS attack after any dose of vaccine.All of them use or have already used some disease-modifying drug,but 1 does not currently use it.4 participants had attacks in the last 2 years (1 unvaccinated patient with 3 attacks;1 patient with 3 attacks-only 1 attack after vaccination; and 2 patients with 1 attack before the beginning of the vaccination).The EDSS remained unchanged for all participants, except for one with a change in EDSS from 1 to 3 due its psychotic condition (psychosis with urinary incontinence).
CONCLUSION
There was no triggering of new clinical MS attacks in patients vaccinated and no worsening of EDSS attributable to vaccination.Side effects to vaccination were present only after ChAdOx1 vaccination,with side effects already reported in the general population in phase III studies.

Palavras Chave

covid-19; vaccine; Multiple Sclerosis